Now showing items 1-16 of 16

    • A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea 

      Lemanne, Dawn; Block, Keith I; Kressel, Bruce R; Sukhatme, Vikas P; White, Jeffrey D (Cureus, 2015)
      We report the case of a 48-year-old man who achieved a complete molecular remission 20 years after a diagnosis of chronic lymphocytic leukemia while using epigallicatechin-3-gallate, an extract of green tea. The patient ...
    • Erratum to: Modeling precision treatment of breast cancer 

      Daemen, Anneleen; Griffith, Obi L; Heiser, Laura M; Wang, Nicholas J; Enache, Oana M; Sanborn, Zachary; Pepin, Francois; Durinck, Steffen; Korkola, James E; Griffith, Malachi; Hur, Joe S; Huh, Nam; Chung, Jongsuk; Cope, Leslie; Fackler, Mary Jo; Umbricht, Christopher; Sukumar, Saraswati; Seth, Pankaj; Sukhatme, Vikas P; Jakkula, Lakshmi R; Lu, Yiling; Mills, Gordon B; Cho, Raymond J; Collisson, Eric A; van’t Veer, Laura J; Spellman, Paul T; Gray, Joe W (BioMed Central, 2015)
      During the type-setting of the final version of the article [1] some of the additional files were swapped. The correct files are republished in this Erratum. The online version of the original article can be found under ...
    • Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans 

      Parikh, Samir Mukund; Mammoto, Tadanori; Schultz, Aylit; Yuan, Hai-Tao; Christiani, David C.; Karumanchi, Subbian Ananth; Sukhatme, Vikas Pandurang (Public Library of Science, 2006)
      Background: Acute respiratory distress syndrome (ARDS) is a devastating complication of numerous underlying conditions, most notably sepsis. Although pathologic vascular leak has been implicated in the pathogenesis of ARDS ...
    • Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells 

      Hasegawa, Masanori; Takahashi, Hidekazu; Rajabi, Hasan; Alam, Maroof; Suzuki, Yozo; Yin, Li; Tagde, Ashujit; Maeda, Takahiro; Hiraki, Masayuki; Sukhatme, Vikas P.; Kufe, Donald (Impact Journals LLC, 2016)
      The xCT light chain of the cystine/glutamate transporter (system XC−) is of importance for the survival of triple-negative breast cancer (TNBC) cells. The MUC1-C transmembrane oncoprotein is aberrantly overexpressed in ...
    • Increased Mobilisation of Circulating Endothelial Progenitors in von Hippel-Lindau Disease and Renal Cell Carcinoma 

      Zurita, A J; Norden-Zfoni, A; George, D; Heymach, J V; Bhatt, Rupal Satish; O'Neill, Allison Frances; Zhang, Liang; Wu, H.K.; Wen, Patrick Yung Chih; Sukhatme, Vikas Pandurang; Atkins, M.B. (Nature Publishing Group, 2011)
      Background: Circulating endothelial cells (CECs) are a candidate biomarker for monitoring angiogenesis in cancer. Circulating endothelial cell subsets are mobilised by angiogenic mediators. Because of the highly angiogenic ...
    • Induction of Erythroid Differentiation in Human Erythroleukemia Cells by Depletion of Malic Enzyme 2 

      Everett, Peter; Clish, Clary B.; Polymenis, Michael; Ren, Jian-Guo; Seth, Pankaj; Sukhatme, Vikas Pandurang (Public Library of Science, 2010)
      Malic enzyme 2 (ME2) is a mitochondrial enzyme that catalyzes the conversion of malate to pyruvate and CO2 and uses NAD as a cofactor. Higher expression of this enzyme correlates with the degree of cell de-differentiation. ...
    • Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling 

      Ren, Jian-Guo; Seth, Pankaj; Clish, Clary B.; Lorkiewicz, Pawel K.; Higashi, Richard M.; Lane, Andrew N.; Fan, Teresa W.-M.; Sukhatme, Vikas P. (Nature Publishing Group, 2014)
      Mitochondrial malic enzyme 2 (ME2) catalyzes the oxidative decarboxylation of malate to yield CO2 and pyruvate, with concomitant reduction of dinucleotide cofactor NAD+ or NADP+. We find that ME2 is highly expressed in ...
    • Modeling precision treatment of breast cancer 

      Daemen, Anneleen; Griffith, Obi L; Heiser, Laura M; Wang, Nicholas J; Enache, Oana M; Sanborn, Zachary; Pepin, Francois; Durinck, Steffen; Korkola, James E; Griffith, Malachi; Hur, Joe S; Huh, Nam; Chung, Jongsuk; Cope, Leslie; Fackler, Mary Jo; Umbricht, Christopher; Sukumar, Saraswati; Seth, Pankaj; Sukhatme, Vikas P; Jakkula, Lakshmi R; Lu, Yiling; Mills, Gordon B; Cho, Raymond J; Collisson, Eric A; van’t Veer, Laura J; Spellman, Paul T; Gray, Joe W (BioMed Central, 2013)
      Background: First-generation molecular profiles for human breast cancers have enabled the identification of features that can predict therapeutic response; however, little is known about how the various data types can best ...
    • Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review 

      Retsky, Michael W.; Demicheli, Romano; Hrushesky, William; Forget, Patrice; Kock, Marc; Gukas, Isaac; Rogers, Rick A.; Baum, Michael; Sukhatme, Vikas Pandurang; Vaidya, Jayant (Bentham Science Publishers Ltd., 2013)
      To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple databases, we proposed that late relapses result from steady stochastic progressions from single dormant ...
    • Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent 

      Pantziarka, Pan; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vidula; Sukhatme, Vikas P (Cancer Intelligence, 2014)
      Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. ...
    • Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent 

      Van Nuffel, An MT; Sukhatme, Vidula; Pantziarka, Pan; Meheus, Lydie; Sukhatme, Vikas P; Bouche, Gauthier (Cancer Intelligence, 2015)
      Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections, treatment of Lyme disease and eradication of gastric infection with ...
    • Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent 

      Pantziarka, Pan; Sukhatme, Vidula; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vikas P (Cancer Intelligence, 2015)
      Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has ...
    • Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent 

      Pantziarka, Pan; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vidula; Sukhatme, Vikas P (Cancer Intelligence, 2014)
      Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, ...
    • Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent 

      Sukhatme, Vidula; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vikas P; Pantziarka, Pan (Cancer Intelligence, 2015)
      Nitroglycerin (NTG), a drug that has been in clinical use for more than a century, has a range of actions which make it of particular interest in an oncological setting. It is generally accepted that the main mechanism of ...
    • Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent 

      Pantziarka, Pan; Bouche, Gauthier; Sukhatme, Vidula; Meheus, Lydie; Rooman, Ilse; Sukhatme, Vikas P (Cancer Intelligence, 2016)
      Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular ...
    • Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology 

      Husain, Zaheed; Seth, Pankaj; Sukhatme, Vikas P (Landes Bioscience, 2013)
      Many malignant cells produce increased amounts of lactate, which promotes the development of myeloid-derived suppressor cells (MDSCs). MDSCs, lactate, and a low pH in the tumor microenvironment inhibit the function of ...